Adjuvant therapy for postmenopausal patients with operable breast cancer who have estrogen receptor or progesteron receptor positive tumor. Tamoxifen vs. letrozole vs. tamoxifen followed by letrozole vs. letrozole followed by tamoxifen

Study Chair
Prof. Beat Thürlimann - St. Gallen, Switzerland

Statisticians
Anita Giobbie-Hurder
Dr. Zhuoxin Sun


Lead Trial Coordinator
Holly Shaw

Data Managers
Susan Fischer
IBCSG Data Management Center/FSTRF
4033 Maple Road
Amherst, New York 14226 USA
Phone: +1 716 834 0900
Fax: +1 716 833 3990
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

Date of Activation
March, 1998

Date of Closure
Core Protocol: May 13, 2003
GS/SLP Substudy: February 7, 2003
BMD Substudy: February 7, 2003
New Bone Substudy: January 31, 2007
Fingernail Pilot Substudy: July 31, 2007
Cognitive Function Substudy: May 20, 2008


Final Accrual
Core Protocol: 8028 patients
GS/SLP Substudy: 65 patients
BMD Substudy: 39 patients
New Bone Substudy: 458 patients
Fingernail Pilot Substudy: 16 patients
Cognitive Function Substudy: 135 patients

International Breast
Cancer Study Group

Effingerstrasse 40
3008 Bern, Switzerland

Contact
Phone: +41 31 511 94 00
E-mail: ibcsgcc@ibcsg.org

Member Login